• Norovirus Co-opts NINJ1 for Selective NS1 Secretion

  2026-09-25

  A 2025 study finds that murine norovirus exploits NINJ1 to release the viral protein NS1, distinguishing selective cargo secretion from the bulk release of cellular damage signals during membrane rupture. The work connects caspase-3 processing of NS1/2 to NINJ1-dependent secretion and shows that disrupting caspase-3 can reduce oral infection in mice.

• CDK8/19 Inhibition and Osteoarthritis: Study Findings

  2026-09-25

  A 2026 study links CDK8/19 inhibition with changes in chondrocyte hypertrophy, inflammatory signaling, cartilage matrix maintenance, and endochondral ossification. Its combination of cell-based assays, human OA tissue, and spontaneous-disease mouse outcomes offers a broader framework for evaluating potential disease modification than cartilage lesion scoring alone.

• Cyclopamine (A8340): Practical Assay Design Guide

  2026-09-24

  A scenario-based guide to using Cyclopamine (SKU A8340) in Hedgehog-pathway and cancer research, with practical guidance on model selection, dosing, solubility, and assay interpretation. It connects product handling information with published findings while distinguishing evidence from workflow recommendations.

• Lanabecestat (AZD3293): Mapping the BACE1 Window

  2026-09-24

  Lanabecestat offers translational researchers a potent tool for studying BACE1 and amyloid-beta production. Evidence from neuronal cultures suggests that the biological consequences of inhibition depend on the degree of amyloid-beta reduction, making exposure-response design and paired synaptic measurements central to rigorous Alzheimer’s disease research.

• Regorafenib Workflows for Melanoma Research

  2026-09-23

  Use Regorafenib (BAY 73-4506) to connect multikinase inhibition with practical assays of melanoma growth, motility, apoptosis, and RRM2-associated signaling. This workflow pairs dose-response controls with migration and mechanistic readouts to help distinguish reduced aggressiveness from general cytotoxicity.

• PD0325901: From MEK Signaling to TERT

  2026-09-23

  PD0325901 is a selective MEK inhibitor for dissecting RAS/RAF/MEK/ERK signaling, cancer phenotypes, and transcriptional regulation. This article develops an assay-centered framework linking pathway inhibition to TERT chromatin control in human pluripotent stem cells.

• APEX2 Enables TERT Expression in Human Stem Cells

  2026-09-22

  This preprint identifies APEX2 as a selective DNA repair factor required for efficient TERT expression and telomerase activity in human embryonic stem cells. RNA-seq and chromatin immunoprecipitation connect APEX2 activity with repetitive DNA elements, particularly MIR sequences within the TERT locus, suggesting that repair of damage-prone repeats may influence transcription.

• Single-Fibre Mapping of Nucleosome Distortion

  2026-09-22

  The reference study introduces IDLI, a computational framework that uses long-read single-molecule footprinting to map structurally distinct nucleosomes and protein–DNA interactions on individual chromatin fibres. Its results indicate that nucleosome distortion is widespread, developmentally regulated, and associated with transcription-factor occupancy, providing a new way to study chromatin accessibility beyond average population-level measurements.

• CUDC-907 Dual PI3K and HDAC Inhibitor Guide

  2026-09-21

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of PI3K/AKT signaling, HDAC activity, cell-cycle progression, and apoptosis. This dossier-based guidance covers formulation, starting conditions, readout selection, and QC; the compound is for scientific research only and not for diagnostic or medical use.

• AICAR phosphate (Acadesine): Assay Guide

  2026-09-21

  A scenario-based guide to using AICAR phosphate (Acadesine), SKU B1211, in viability, proliferation, and apoptosis workflows. It covers dose selection, solution handling, orthogonal readouts, cross-domain interpretation, and practical criteria for evaluating product reliability.

• PLAC1 Targeting in Clear Cell Renal Cell Carcinoma

  2026-09-20

  A 2025 Cellular Signalling study identifies PLAC1 as a prognostic biomarker and candidate molecular target in clear cell renal cell carcinoma (ccRCC). By combining TCGA analysis, protein-level validation, PLAC1 knockdown, and high-throughput virtual screening, the researchers nominate Amaronol B and Canagliflozin as compounds that reduce PLAC1-associated ccRCC progression in vitro.

• Trametinib (GSK1120212): Assay Reliability

  2026-09-19

  This scenario-driven guide shows how Trametinib (GSK1120212), SKU A3018, can help researchers interpret variable viability, proliferation, and cytotoxicity results through mechanism-aware experimental design. It covers model selection, DMSO stock preparation, pathway-confirming readouts, heterogeneity, and practical vendor evaluation.

• BI-1347: CDK8 Signaling Workflow Guide

  2026-09-18

  BI-1347 is a potent, selective small-molecule probe for testing target-dependent signaling and antitumor biology. This workflow translates CDK8/19-focused findings from osteoarthritis research into practical cell-based, inflammatory, transcriptomic, and translational assay designs.

• Nilotinib (AMN-107) Assay Workflows

  2026-09-18

  Build more informative kinase-response experiments with Nilotinib (AMN-107), from BCR-ABL target engagement to separate measurements of growth arrest and cell death. This workflow combines practical dosing guidance, mutation-aware comparisons, and troubleshooting for chronic myeloid leukemia research and KIT-driven models.

• CUDC-907: Practical Dual PI3K/HDAC Workflow

  2026-09-17

  CUDC-907 provides a research tool for examining concurrent PI3K/AKT signaling pathway inhibition and histone deacetylase inhibition in controlled cancer cell assays. This guide covers preparation, exposure, controls, and endpoint QC; the compound is for research use only and should not be used for diagnostic, therapeutic, or clinical applications.

7742 records 1/517 page Next 12345 下5页 Last page